glp 1 agonist crohn's disease SAFETY AND CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL PATIENTS The Potential for GLP-1s in
Description
Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al
Karwi QG, Biswas D, Pulinilkunnil T, Lopaschuk GD
The truth is, GLP-1s are not for everyone clinical studies have found that just over 10% of patients do not lose weight on semaglutide, while others cant tolerate certain side effects and have to stop taking the drug
SYSTEMIC EFFECTS Research regarding the application of these medications is ongoing
